Functional and structural analysis of AT-specific minor groove binders that disrupt DNA-protein interactions and cause disintegration of the Trypanosoma brucei kinetoplast
- PMID: 28637278
- PMCID: PMC5737332
- DOI: 10.1093/nar/gkx521
Functional and structural analysis of AT-specific minor groove binders that disrupt DNA-protein interactions and cause disintegration of the Trypanosoma brucei kinetoplast
Abstract
Trypanosoma brucei, the causative agent of sleeping sickness (Human African Trypanosomiasis, HAT), contains a kinetoplast with the mitochondrial DNA (kDNA), comprising of >70% AT base pairs. This has prompted studies of drugs interacting with AT-rich DNA, such as the N-phenylbenzamide bis(2-aminoimidazoline) derivatives 1 [4-((4,5-dihydro-1H-imidazol-2-yl)amino)-N-(4-((4,5-dihydro-1H-imidazol-2-yl)amino)phenyl)benzamide dihydrochloride] and 2 [N-(3-chloro-4-((4,5-dihydro-1H-imidazol-2-yl)amino)phenyl)-4-((4,5-dihydro-1H-imidazol-2-yl)amino)benzamide] as potential drugs for HAT. Both compounds show in vitro effects against T. brucei and in vivo curative activity in a mouse model of HAT. The main objective was to identify their cellular target inside the parasite. We were able to demonstrate that the compounds have a clear effect on the S-phase of T. brucei cell cycle by inflicting specific damage on the kinetoplast. Surface plasmon resonance (SPR)-biosensor experiments show that the drug can displace HMG box-containing proteins essential for kDNA function from their kDNA binding sites. The crystal structure of the complex of the oligonucleotide d[AAATTT]2 with compound 1 solved at 1.25 Å (PDB-ID: 5LIT) shows that the drug covers the minor groove of DNA, displaces bound water and interacts with neighbouring DNA molecules as a cross-linking agent. We conclude that 1 and 2 are powerful trypanocides that act directly on the kinetoplast, a structure unique to the order Kinetoplastida.
© The Author(s) 2017. Published by Oxford University Press on behalf of Nucleic Acids Research.
Figures









References
-
- World Health Organization and Department of control of neglected tropical diseases Report of the second WHO stakeholders meeting on gambiense human African trypanosomiasis elimination. 2016; Geneva: 21–23.
-
- Delespaux V., de Koning H.P.. Drugs and drug resistance in African trypanosomiasis. Drug Resist. Updat. 2007; 10:30–50. - PubMed
-
- Ríos Martínez C.H., Nué Martínez J.J., Ebiloma G.U., de Koning H.P., Alkorta I., Dardonville C.. Lowering the pKa of a bisimidazoline lead with halogen atoms results in improved activity and selectivity against Trypanosoma brucei in vitro. Eur. J. Med. Chem. 2015; 101:806–817. - PubMed
-
- Ríos Martínez C.H., Miller F., Ganeshamoorthy K., Glacial F., Kaiser M., de Koning H.P., Eze A.A., Lagartera L., Herraiz T., Dardonville C.. A new nonpolar N-hydroxy imidazoline lead compound with improved activity in a murine model of late-stage Trypanosomabrucei brucei infection is not cross-resistant with diamidines. Antimicrob. Agents Chemother. 2015; 59:890–904. - PMC - PubMed
-
- Dardonville C., Barrett M.P., Brun R., Kaiser M., Tanious F., Wilson W.D.. DNA binding affinity of bisguanidine and bis(2-aminoimidazoline) derivatives with in vivo antitrypanosomal activity. J. Med. Chem. 2006; 49:3748–3752. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous